343 related articles for article (PubMed ID: 37040734)
1. Real-Life Experience and Predictors of Visual Outcomes with Intravitreal Brolucizumab Switch for Treatment of Neovascular Age-Related Macular Degeneration.
Cavalleri M; Tombolini B; Sacconi R; Gatta G; Valeri R; Bandello F; Querques G
Ophthalmologica; 2023; 246(2):158-168. PubMed ID: 37040734
[TBL] [Abstract][Full Text] [Related]
2. Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment.
Chronopoulos A; Huynh E; Ashurov A; Schutz JS; Jonas JB; Hattenbach LO
Eur J Ophthalmol; 2024 Mar; 34(2):487-496. PubMed ID: 37461836
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies.
Baumal CR; Sørensen TL; Karcher H; Freitas RL; Becher A; Balez S; Clemens A; Singer M; Kodjikian L
Acta Ophthalmol; 2023 Mar; 101(2):123-139. PubMed ID: 36117281
[TBL] [Abstract][Full Text] [Related]
4. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
[TBL] [Abstract][Full Text] [Related]
5. [Real-life experiences with Brolucizumab in recalcitrant neovascular age-related macular degeneration].
Book M; Ziegler M; Rothaus K; Faatz H; Gutfleisch M; Spital G; Lommatzsch A; Pauleikhoff D
Ophthalmologe; 2022 Mar; 119(3):258-264. PubMed ID: 34351479
[TBL] [Abstract][Full Text] [Related]
6. Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration.
Enríquez AB; Baumal CR; Crane AM; Witkin AJ; Lally DR; Liang MC; Enríquez JR; Eichenbaum DA
JAMA Ophthalmol; 2021 Apr; 139(4):441-448. PubMed ID: 33630045
[TBL] [Abstract][Full Text] [Related]
7. Brolucizumab for Wet Age-Related Macular Degeneration: One-Year Real-World Experience from a Tertiary Center.
Scupola A; Carlà MM; Boselli F; Giannuzzi F; De Filippis A; Fossataro C; Minnella AM; D'Amico G; Coppola G; Savastano MC; Sammarco MG; Rizzo S
Ophthalmologica; 2023; 246(1):58-67. PubMed ID: 36843038
[TBL] [Abstract][Full Text] [Related]
8. One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS® Registry.
MacCumber MW; Wykoff CC; Karcher H; Adiguzel E; Sinha SB; Vishwakarma S; LaPrise A; Igwe F; Freitas R; Ip MS; Zarbin MA
Ophthalmology; 2023 Sep; 130(9):937-946. PubMed ID: 37086857
[TBL] [Abstract][Full Text] [Related]
9. Association Between Visual Acuity and Residual Retinal Fluid Following Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-analysis.
Patil NS; Mihalache A; Dhoot AS; Popovic MM; Muni RH; Kertes PJ
JAMA Ophthalmol; 2022 Jun; 140(6):611-622. PubMed ID: 35551359
[TBL] [Abstract][Full Text] [Related]
10. Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration.
Maruyama-Inoue M; Yanagi Y; Inoue T; Kadonosono K
Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):589-599. PubMed ID: 37750953
[TBL] [Abstract][Full Text] [Related]
11. Real-world experience with brolucizumab in neovascular age-related macular degeneration over 2 years: the REBA extension study.
Bilgic A; Kodjikian L; de Ribot FM; Spitzer MS; Vasavada V; Gonzalez-Cortes JH; Sudhalkar A; Chakraborty S; Mathis T
Graefes Arch Clin Exp Ophthalmol; 2024 Apr; 262(4):1161-1167. PubMed ID: 38063874
[TBL] [Abstract][Full Text] [Related]
12. Changes in the uninjected contralateral eye after intravitreal brolucizumab for exudative age-related macular degeneration.
Mora P; Bellucci C; Radice LM; Manzotti F; Gandolfi S
Eur J Ophthalmol; 2024 Jan; 34(1):NP104-NP107. PubMed ID: 37424299
[TBL] [Abstract][Full Text] [Related]
13. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
Nguyen QD; Das A; Do DV; Dugel PU; Gomes A; Holz FG; Koh A; Pan CK; Sepah YJ; Patel N; MacLeod H; Maurer P
Ophthalmology; 2020 Jul; 127(7):963-976. PubMed ID: 32107066
[TBL] [Abstract][Full Text] [Related]
14. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
[TBL] [Abstract][Full Text] [Related]
15. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
Sci Rep; 2022 May; 12(1):8195. PubMed ID: 35581196
[TBL] [Abstract][Full Text] [Related]
16. A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration-the FALCON study.
Holz FG; Schmitz-Valckenberg S; Wolf A; Agostini H; Lorenz K; Pielen A; Feltgen N; Guthoff R; Quiering C; Clemens A; Jaeger K
Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2695-2702. PubMed ID: 35188581
[TBL] [Abstract][Full Text] [Related]
17. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study.
Bulirsch LM; Saßmannshausen M; Nadal J; Liegl R; Thiele S; Holz FG
Br J Ophthalmol; 2022 Sep; 106(9):1288-1294. PubMed ID: 33846161
[TBL] [Abstract][Full Text] [Related]
18. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
[TBL] [Abstract][Full Text] [Related]
19. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
[TBL] [Abstract][Full Text] [Related]
20. Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study.
Tamashiro T; Tanaka K; Itagaki K; Nakayama M; Maruko I; Wakugawa S; Terao N; Onoe H; Wakatsuki Y; Ogasawara M; Sugano Y; Yamamoto A; Kataoka K; Izumi T; Kawai M; Mori R; Sekiryu T; Okada AA; Iida T; Koizumi H;
Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1857-1865. PubMed ID: 35034215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
